---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-025175"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:58:59.489890+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GeoVax reports Q2 net loss of $5.1M; awarded up to $388M BARDA contract for COVID vaccine trial

## Summary
- Net loss $5.1M ($1.99/share) vs $5.9M ($3.79) in Q2 2023; R&D expenses $4.3M.
- BARDA Project NextGen award for GEO-CM04S1 Phase 2b trial; total value $367-388M incl. Allucent.
- Cash $1.56M at June 30, 2024, down from $6.45M at Dec 31, 2023.
- Gedeptin advanced to expanded Phase 2 trial for head and neck cancer; activation H1 2025.
- Commercial manufacturing platform for GEO-CM04S1 established with Oxford Biomedica.

## SEC filing metadata
- accession: 0001437749-24-025175
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774924025175/0001437749-24-025175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774924025175/govx20240806_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-025175
- JSON: https://secwatch.observer/filing/0001437749-24-025175.json
- Plain text: https://secwatch.observer/filing/0001437749-24-025175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.